Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study observed that higher childhood levels of DHEAS were associated with more advanced pubertal development and correlated with changes in DNA methylation near puberty-related genes in both boys and girls, potentially explaining the hormone's influence on puberty.

Finasteride can cause enlarged breasts.

This study observed that although 5-alpha-reductase inhibitors reduce PSA density in patients on active surveillance for prostate cancer, those who progress to more serious disease still show higher PSA densities, suggesting these inhibitors accentuate differences in clinically significant cases.

This study found that the detection rate of clinically insignificant prostate cancer increases with the number of repeat prostate biopsies in patients with persistently suspicious prostate cancer.

This study found that epitestosterone acts as a weak antiandrogen by inhibiting receptor binding and 5α-reductase activity in animal models.

This paper discusses prostate cancer diagnosis and treatment controversies and advocates for individualized approaches, reporting no new findings.

In this animal study, researchers found that finasteride reduced bacterial infection and inflammation in chronic bacterial prostatitis, with the greatest effect when combined with ciprofloxacin.

This review covers recent advances in prostate cancer risk assessment, diagnosis, and treatment but does not report new clinical results; further studies on androgen deprivation therapy's cardiovascular risks are particularly noted.

This review reports that combination therapy with 5α-reductase inhibitors and α1-receptor blockers does not appear to benefit patients with benign prostatic hyperplasia and prostate volumes up to 40–45 ml, but may be more effective for larger prostate volumes.

This study found that using 5α-reductase inhibitors during active surveillance for low-risk prostate cancer reduced prostate volume by 23% and was associated with a lower progression rate.

This review discusses the use of 5α-reductase inhibitors in treating benign prostatic hyperplasia, highlighting their long-term effectiveness and benefits when combined with α1-adrenergic antagonists; it reports no new clinical results.

This study investigated the metabolic pathways of epristeride, a new Type II 5α‐reductase inhibitor, using in vitro models and found that its metabolites show significant interactions with key proteins, suggesting implications for its role in doping control.

This review summarizes a meta-analysis suggesting that finasteride is most effective for improving symptoms and urinary flow in men with large prostates experiencing benign prostatic hyperplasia.

This report describes a complex case of postmenopausal hyperandrogenism with virilization and concurrent rare ovarian tumors, highlighting the critical role of interdisciplinary collaboration in diagnosing and managing such challenging scenarios.

This study found that the combination therapy of Flosin and Prostamol Uno over nine years was well tolerated and equally effective in managing benign prostatic hyperplasia symptoms as the combination of doxazosin and finasteride, with fewer adverse events reported.

This review discusses the expression of PSA in hormonally-regulated tissues and female malignancies, emphasizing its potential as a diagnostic biomarker and role in antidoping initiatives.

This case report illustrates a rare instance of mixed germ cell tumor in the pituitary with hyperandrogenism, emphasizing the importance of thorough examination and hormone evaluation in identifying hormonal dysfunctions.

In this case report, a 72-year-old man was initially misdiagnosed with a bladder tumor but was later accurately diagnosed with eosinophilic cystitis through pathological examination; transurethral resection and combined drug treatment improved his condition with no recurrence over six months.

This case report illustrates that Leydig cell tumors, despite causing significantly elevated androgen levels, can be difficult to localize due to their small size, as demonstrated in a 42-year-old woman whose tumor was only identified after oophorectomy.

This study found that overexpression of AKR1C3 in prostate cancer cells redirected androgen metabolism towards testosterone production, which facilitated cell proliferation, potentially reducing the effectiveness of finasteride treatment.

This study identified that derivatives 4, 4b, and 4c strongly inhibited the enzyme type 1 5α-reductase and decreased reproductive organ weights in hamsters, suggesting potential as prodrugs for prostate tumor growth inhibition.

This update provides information on new drug approvals but does not offer new clinical research findings.

This study found that α-spinasterol treatment significantly reduced testosterone propionate-induced prostatic hyperplasia in rats, suggesting potential benefits for managing benign prostatic hyperplasia.

This article discusses the implications of finasteride on serum PSA levels and questions the routine recommendation for prostate biopsy at specific PSA thresholds, urging reevaluation of prostate cancer detection methods; it reports no clinical results.

In this study, micro-CT analysis revealed that severe hypospadias in finasteride-induced rats was associated with varying levels of preputial blood circulation, impacting potential surgical approaches.

Finasteride effectively lowers specific hormone levels, helping monitor treatment progress.

This study found that low doses of bisphenol A may increase proliferation of the ventral prostate in adult rats by altering the estrogen to androgen ratio and gene expression.

In this study, reduced androgen receptor gene methylation and shorter CAG repeats in children with premature pubarche may lead to increased hair follicle sensitivity to steroid hormones, potentially causing early pubic hair development.

Combining different treatments may be needed to effectively manage chronic prostatitis.

This meeting abstract details various lectures and workshops from the 30th Annual Meeting of the American Society of Andrology, including findings on genetic and physiological factors affecting male fertility, but reports no new clinical results.